Tango Therapeutics, Inc. TNGX

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

• Zacks Investment Research 10 sept

  Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

  Tango Therapeutics (TNGX) stock has declined 6.2% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss of 37 cents per share due to higher operating expenses, with R&D expenses up 13% and G&A expenses nearly doubling. Collaboration revenues dropped to zero from $3.2 million year-over-year following the conclusion of its Gilead partnership. Analyst estimates have shifted downward by 10.16% in the past month, and the stock carries a Zacks Rank #3 (Hold) with poor VGM scores across growth, momentum, and value metrics.

  

• GlobeNewswire Inc. 25 ago

  Tango Releases Controlling the Sequence: The 2026 Retail Real Estate Portfolio Execution Index

  A new retail real estate portfolio execution index reveals that nearly all large retailers (97.6%) experience downstream problems from lease management decisions. The report finds that retailers manage roughly one major real estate project per week, but only 17% receive automated alerts for lease deadlines. Retailers using integrated third-party systems report significantly higher satisfaction (47%) compared to those using disconnected systems (19%), highlighting the competitive advantage of portfolio-level visibility and coordination.

  

• GlobeNewswire Inc. 6 ago

  Tango Therapeutics Announces Executive Chair Transition

  Dr. Barbara Weber, Executive Chairman of Tango Therapeutics (NASDAQ: TNGX), is stepping down to pursue other interests. The clinical-stage biotechnology company, which focuses on precision cancer medicines using synthetic lethality principles, expressed gratitude for Weber's leadership and vision while affirming confidence in the company's future direction under President Dr. Malte Peters.

  

• GlobeNewswire Inc. 9 jun

  Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

  Tango Therapeutics priced an underwritten offering of 18.2 million shares at $30.00 per share and pre-funded warrants, expected to raise approximately $600 million in gross proceeds. The offering is expected to close on June 11, 2026, with J.P. Morgan, Leerink Partners, Cantor, and Stifel serving as joint bookrunning managers.